Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. (22nd November 2021)

• Record Type: Journal Article
• Authors: Papaefthymiou, Apostolis; Potamianos, Spyros; Goulas, Antonis; Doulberis, Michael; Kountouras, Jannis; Polyzos, Stergios A
• Is Part Of: Journal of Crohn's and colitis. Volume 16:Number 5(2022)
• Page Start: 852
• Page End: 862
• Publication Date: 2021-11-22
• Subjects: Biologics -- inflammatory bowel diseases -- nonalcoholic fatty liver disease; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjab212
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Inflammatory bowel diseases [IBD] exhibit intestinal and systemic manifestations. Nonalcoholic fatty liver disease [NAFLD] is a common co-existing condition, possibly contributing to the cardio-metabolic burden and overall morbidity. Εmerging therapeutic choices of biologic agents have modified the clinical course of IBD; however, their impact on IBD-associated NAFLD has not been extensively evaluated. The prevalence of NAFLD varies among IBD patients, but it appears higher than in the general population in the majority of quality studies. In terms of pathogenetic and risk factors of NAFLD, they may vary with IBD activity. Dysbiosis, mucosal damage, and cytokine release have been implicated in the pathogenesis during the relapses, whereas metabolic risk factors seem to play a dominant role during the remissions of IBD. Considering biologics, although quality data are scarce, agents suppressing tumour necrosis factor may offer potential benefits in IBD-associated NAFLD, whereas anti-integrins do not appear to confer any therapeutic advantage. In conclusion, IBD-associated NAFLD possibly follows two different patterns, one manifested during the relapses and one during the remissions of IBD. Some, but not all, biologics may benefit NAFLD in patients with IBD. Further mechanistic and prospective cohort studies are warranted to illuminate the effects of various biologics on NAFLD.